<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924014</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <secondary_id>IND 104, 334</secondary_id>
    <nct_id>NCT00924014</nct_id>
  </id_info>
  <brief_title>Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure</brief_title>
  <official_title>Comparative Effects of Conivaptan and Loop Diuretics on Plasma Neurohormones and Systemic and Renal Hemodynamics in Subjects With Chronic Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin County Medical Center, Minneapolis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hennepin County Medical Center, Minneapolis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effects of conivaptan and diuretics on renal blood
      flow and neurohormones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To define the hemodynamic, neurohormonal and renal responses to intravenous conivaptan
           in patients with chronic stable heart failure (HF), and compare these responses to those
           after intravenous furosemide.

        2. To define the hemodynamic, neurohormonal and renal responses to the combination of the
           two drugs (conivaptan and furosemide).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal hemodynamics renal blood flow and glomerular filtration rate</measure>
    <time_frame>measured on days 1, 2, 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure plasma neurohormone levels</measure>
    <time_frame>predose, 1 hour and 4 hours post dose measured on day 1, 2, 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conivaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conivaptan will be given via IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide will be given via IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conivaptan and furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>on day 3 subjects will receive both study drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan</intervention_name>
    <description>Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr</description>
    <arm_group_label>Conivaptan</arm_group_label>
    <other_name>vaprisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.</description>
    <arm_group_label>Furosemide</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan and furosemide</intervention_name>
    <description>Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours</description>
    <arm_group_label>conivaptan and furosemide</arm_group_label>
    <other_name>vaprisol</other_name>
    <other_name>lasix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of chronic congestive heart failure of any etiology

          -  Be between 18-80 years of age

          -  Able to provide consent

          -  Have a documented left ventricular ejection fraction within the last year of &lt; 40%

          -  On a stable dose (no changes within 2 weeks) of 40 mg or greater daily dose of
             furosemide or its equivalent

          -  On standard HF therapy medications (ACEI or ARB and beta-blocker unless
             contraindicated)

          -  Have an estimated glomerular filtration rate (GFR) of 30 ml/minute or greater (based
             on the Cockcroft Gault calculation)

          -  Have a hemoglobin of &gt; 10 grams/dl

          -  Have a negative urine pregnancy for women of childbearing years only

        Exclusion Criteria:

          -  Acute coronary syndrome within 1 month

          -  Systolic blood pressure less than or equal to 90 mmHg at time of enrollment

          -  Poor peripheral venous access

          -  Severe concomitant disease which deemed by the investigator would render them
             unsuitable for this trial

          -  Allergy or contraindication to the use of iothalamate, PAH - Specifically any
             allergies to iodine or iodine containing products, history of asthma and hay fever
             which deemed by the investigator would render them unsuitable for this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Goldsmith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shari Mackedanz, RN BSN</last_name>
    <phone>612-347-5195</phone>
    <email>shari.mackedanz@hcmed.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hennepin county Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven R Goldsmith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>June 17, 2009</last_update_submitted>
  <last_update_submitted_qc>June 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steven R. Goldsmith</name_title>
    <organization>Hennepin County Medical Center</organization>
  </responsible_party>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Conivaptan</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

